The new weekly 120mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.

If approved, the neonatal Fc receptor blocker would become the first FDA-authorized therapy specifically indicated for patients with wAIHA.

A proprietary extended-release oral minoxidil, VDPHL01, shows superior efficacy and a consistent safety profile vs placebo for hair loss in men.

Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.

Zanidatamab plus chemotherapy with or without tislelizumab significantly improves progression free survival in first-line ...

New long-term data from Study 304 confirms lumateperone 42mg significantly delays time to relapse in clinically stable patients with schizophrenia.

About one-third of children and adolescents use dietary supplements in the US, according to a study published online April 24 in Pediatrics Open Science. Brandy ...

Treatment with three low-dose agents in single pill linked to lower incidence of recurrent stroke, major cardiovascular events in patients with hemorrhagic stroke ...

Officials say the move conflicts with past promises to limit ties between the government and the tobacco industry.

Early signs include a high fever, cough, runny nose and red, watery eyes. A red rash that starts at the hairline usually appears three to five days later. People can spread the virus from 4 days ...

The NDA submission included data from the STRIVE-ON trial, which compared GTx-104 with oral nimodipine in patients ...

The expanded approval was based on the single-arm, non-randomized, open-label phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of teplizumab.